The National Institute for Health and Care Excellence (NICE) has issued final draft guidance allowing children with spinal muscular atrophy (SMA) in England, Wales, and Northern Ireland to access two crucial drugs: nusinersen (Spinraza) and risdiplam (Evrysdi). This decision is a significant breakthrough for approximately 1,150 children under 18 in England and offers hope to families previously facing devastating outcomes. SMA is a genetic disorder characterized by severe muscle weakness, often leading to reduced life expectancy, particularly in its most severe form, type 1, where children typically do not survive past two years. NHS England's national medical director, Prof James Palmer, emphasized the transformative impact of these treatments, stating they provide a new hope for families. One parent, Portia Thorman, shared her son Ezra's journey, highlighting how nusinersen has dramatically changed his life since he began treatment at five months old. The NHS has reached pricing agreements with the drugs' manufacturers, Biogen and Roche Pharmaceuticals, to ensure their long-term availability. Additionally, there are ongoing discussions about implementing newborn screening for SMA, which could further improve early detection and treatment opportunities.